

The U. S. Army Reactive Topical Skin Protectant (rTSP): Challenges and Successes⁺⁺

Stephen T. Hobson^{*}, Erich K. Lehnert, and Ernest H. Braue Jr.

Drug Assessment Division, U. S. Army Medical Research Institute of Chemical Defense,
Aberdeen Proving Ground, MD 21010-5400, USA

ABSTRACT

In 1994, the U. S. Army initiated a research effort towards an effective material that acts both as a protective barrier and as an active destructive matrix against chemical warfare agents (CWA). We report results on our preparation and evaluation of Reactive Topical Skin Protectants (rTSP's). These creams are composite materials consisting of a base material (TSP) and a reactive moiety. Using an established base of perfluorinated-polyether and perfluoropolyethylene solids we incorporated over 60 reactive components. Classes tested include organic polymers, organic/inorganic hybrid materials, polyoxometallates (POM's), enzymes, inorganic oxides, metal alloys and small molecules. We characterized these materials by light microscopy and FTIR. We determined the efficacy of these materials against both sulfur mustard (HD) and a representative nerve agent, soman (GD), using a penetration cell model coupled to a continuous air monitor and also by *in vivo* testing. Composite materials with optimum reactive compounds exhibit a 94% reduction of GD vapor break-through after 20 hours (from 9458 ng to 581 ng) and a 3.6 fold increase (from 162 min to 588 min) in the time 1000 ng of GD liquid penetrates through the material. Similar composite materials show a 99% reduction in HD vapor break-through after 20 hours (from 4040 ng to 16 ng), a 2.3 fold increase (from 524 min to >1200 min) in the time 1000 ng of HD vapor penetrates through the material, and an elimination of erythema versus control in an HD vapor challenge. These results indicate that an rTSP that protects against sulfur mustard and nerve agents is within reach.

INTRODUCTION

Chemical warfare agents (CWA's) represent a real and growing threat both to U.S. Armed Forces as well as to civilians. Within the last three decades, chemical weapons have been used by the Soviets in Cambodia (yellow rain, tricothecene mycotoxins) [1], by Iraq against Iran (HD and tabun) [2], and by Iraq against its own dissident Kurdish population at Halabja (HD, HCN_(g)) [3]. In the United States' experience in World War I, almost one-third of hospitalized casualties were a result of CWA's [4]. Furthermore, the 1995 use of sarin in a terrorist attack in Tokyo, Japan, which resulted in over 1000 casualties and 12 deaths [5], demonstrates that the civilian population has also become a target.

The United States Army classifies CWA's into seven categories [6]. However, in this paper we will focus only on protection against two classes: nerve agents (soman, GD) and blister agents (sulfur mustard, HD). Currently, protection against these agents in the United States Army consists of a chemically resistant outer layer of clothing (BDO) and protective mask (M40) [7]. This scheme of protection does allow continued operation in a chemically contaminated area but results in decreased performance as well as increased heat retention. In a continuing effort to develop a barrier to CWA's that will increase protection without degrading performance, we have investigated a material that serves as a physical barrier to these agents *and* contains an active moiety to neutralize any chemicals that contact this material. This Reactive

Topical Skin Protectant (rTSP) would be used in conjunction with other protective procedures. Herein we report the preparation, characterization, and evaluation of rTSP's.

EXPERIMENTAL DETAILS

Polytetrafluoroethylene (PTFE) resin (Polymist F[®]) and propene hexafluoro oxidized polymerized oil (Fomblin[®]) were obtained from Ausimont USA Inc. (Thorofare, NJ). Proprietary reactive moieties were received from extramural contractors through Small Business Innovation Research (SBIR) contracts or direct support of academic investigators. S-330 (1,3,4,6-tetrachloro-7, 8-diimino glycouril) was obtained from Monsanto and used without further purification. Iodobenzene diacetate (IBDA) and diisopropylfluorophosphate (DFP) were purchased from Aldrich Chemical Company. Ambergard[®] XE-555 resin was obtained from Rohm and Haas Co. (Philadelphia, PA) as part of a M-291 Decontamination Kit. Sulfur Mustard (HD, bis-(2-chlorethyl) sulfide) and soman (GD, pinacolyl methyl phosphonofluoridate) were obtained from Edgewood Research and Development and Engineering Center (ERDEC). NMR spectra were recorded on a Varian Unity INOVA NMR at the appropriate frequency (¹H: 600 MHz, ¹³C: 150 MHz, ³¹P 242 MHz). FTIR spectra were run on a Nicolet 360 Avatar FTIR system. Experimental details of the *in vitro* and *in vivo* analysis of rTSP's have been reported previously [8].

Formulation of rTSP's followed as closely as possible the technique used for the production of a *non*-reactive topical skin protectant (TSP) base cream [9]. In general, the reactive moiety is suspended in either Fomblin[®] or Polymist F[®] by mechanical or manual stirring. The other polymer is added in portions with vigorous mechanical stirring. As a representative example, Polymist F[®] and S-330 were premixed by hand. Into a white polypropylene container is added Fomblin[®]. To the clear, colorless liquid the mixture of PTFE and S-330 is added in two portions. After each addition, the opaque tan suspension is agitated by a mechanical stirrer for 5 minutes resulting in a smooth, off-white cream. The container is closed and sealed with parafilm to exclude moisture.

RESULTS

Two criteria constrain our selection of reactive components. First, the barrier properties of the base cream must not be degraded by the incorporation of the compound(s). Second, the reactive moiety must neutralize CWA's in the environment of the base cream (perfluorinated polyether/PTFE). We have investigated over 60 reactive moieties (Table I).

Table I. Classes of Reactive Moieties.

Class of Reactive	Example
Organic Molecule	S-330, Iodobenzenediacetate
Inorganic Compounds	Polymer coated metal alloys (TiFeMn, MgNi, CaNi), Nanoscale metal oxides (MgO, CaO, TiO ₂), Polyoxometallates
Organic polymers	Dendrimers, Bridged Polysilsesquioxanes, XE-555 resin
Enzymes	Organophosphorous Acid Anhydride Hydrolase (OPAA) Crosslinked Enzyme Crystals (CLEC's)

These compounds have been formulated into over 200 rTSP's and have been evaluated by both *in vivo* and *in vitro* testing. Among these reactive compounds, two oxidizing organic compounds, S-330 and IBDA, have shown particular efficacy against sulfur mustard (HD) (Figure 1).




Figure 1. Organic Reactive Moieties.

In addition to the organic reactive compounds, other compounds have also shown efficacy against HD (inorganic compounds, polysilsesquioxanes, XE-555 resin), GD (OPAA enzymes, CLEC's) or both (dendrimers).

Both the reactive moieties described above as well as other compounds not listed were formulated into rTSP's at various loading percentages. The rTSP's are opaque white or off-white creams. As expected, FTIR analysis shows peaks in the region of C-O-C (1116 cm^{-1}), CF_2 (1198 cm^{-1}), and CF_3 (1259, 978 cm^{-1}) bands [10]. To evaluate the rTSP's we developed a Decision Tree Network that contains various *in vitro* and *in vivo* models [8]. We used a penetration cell test to measure the increase in protection of the rTSP versus the Topical Skin Protectant (Figure 2).





Figure 2. Schematic of penetration cell with saturated vapor setup.

The quantity of either GD or HD is periodically monitored using a miniature continuous air monitoring system (MINICAMS[®]) for 20 hours [11]. From these data, we obtain two values: the cumulative amount of CWA that penetrates through the rTSP; and the time at which a "break-through" occurs. We defined "break-through" values at the minimum amount of HD [12] and GD [13] (1000 ng) that results in a physiological response. These two values allow us to rank the rTSP formulations and to select the appropriate component for advanced development (Figure 3).

All rTSP's that have shown efficacy against GD contain water, and thus we conclude that the reactive component acts as a catalyst for the hydrolysis of soman (Scheme 2).



Scheme 2. Hydrolyses of soman (GD) with dendrimer catalyst.

In preliminary studies of the hydrolysis of a GD simulant (diisopropylfluorophosphate, DFP), we have demonstrated that the hydrolysis of nerve agents is easily monitored by ^{31}P NMR (Figure 5).




Figure 5. Hydrolysis of DFP with dendrimer monitored by ^{31}P NMR (starting at bottom of spectra, time = 0, 2, 4, 6, 8, 10, 14 hr).

In addition to the tests described above, we have also conducted extensive *in vivo* experiments. For example, we assessed the protection of the rTSP against HD vapor using a weanling pig model [8]. In this model, the protection afforded by the rTSP is correlated to the degree of erythema (Figure 6).




Figure 6. Protection of rTSP vs. HD vapor in weanling pig model (Control = no TSP).

A comparison of the animal data presented above and the penetration data presented in Figure 4 shows inconsistent results (Table II).

Table II. Contrasting efficacy against HD vapor penetration from *in vitro* and *in vivo* rTSP evaluation.

Reactive Component	Penetration Cell (ng at 20 hrs, % reduction.)	Weanling Pig (erythema, % of control)	Agreement
TSP	4037 ng, 0%	122%	Y
S330	60 ng, 98%	2.6%	Y
IBDA	9 ng, 99%	11%	Y
Dendrimer	507 ng, 88%	318%	N
Polysilsesquioxane	307 ng, 93%	123%	N
Polyoxometalate	130 ng, 96%	71%	N

Whereas reactive moieties such as small organic molecules (S-330 and IBDA) show protection in the penetration cell test and the weanling pig test, other classes of reactive moieties display seemingly contradictory results. As seen above, the rTSP's containing bridged polysilsesquioxanes, dendrimers, and polyoxometalates reduced the cumulative amount of HD vapor in the penetration cell by 88-96%. However, the recorded erythema from HD vapor in these rTSP's is only slightly decreased or actually increased above control in the *in vivo* test. We have seen similar trends with other compounds and have four possible explanations. First, the skin is occluded by the rTSP, increasing agent penetration and thus the observed erythema. Second, the skin may be sensitized by the rTSP, and thus the small amount of HD vapor that penetrates the skin results in greater erythema. Third, the skin may be irritated by the reaction products. And fourth, agent may penetrate the rTSP during exposure and not be completely removed by the cleaning procedure.

CONCLUSION

We have reported the preparation and evaluation of Reactive Topical Skin Protectants. We developed these composite materials with optimum reactive compounds from the classes of small organic molecules, organic polymers, inorganic materials, and enzymes. Thus far, the optimum formulations display excellent resistance against GD (94% reduction of break-through after 20 hr) and HD (99% reduction in vapor break-through after 20 hours). These materials continue to move towards advanced development with the ultimate goal of complete protection for U.S. soldiers and civilians against CWA's.

ACKNOWLEDGEMENTS

This work was supported by the Department of the Army under a Science and Technology Objective. We would like to thank Neil Lewis and Bryce Doxzon for their work on the penetration cell testing. We would also like to thank Patty DiLeonardi, Joy Knickman, and Tara Nohe for their hard work on formulations. Finally, we would like to thank the United States Army Medical Research Institute of Chemical Defense for encouraging and supporting the presentation and publication of this work.

REFERENCES

- + The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Army or the Department of Defense. In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals" of the Institute of Laboratory Animal Resources, National Research Council.
- ◆ This article is a US Government work and is in the public domain in the United States.
- * Correspondence to: CPT Stephen T. Hobson, Ph.D., Advanced Assessment Branch, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5405, USA.
- 1. R. L. Bartley and W. P. Kucewicz, , *Foreign Affairs*, **61**, 805-826 (1993).
- 2. UN Security Council, *Report of the Specialists Appointed by the Secretary-General to Investigate Allegations by the Islamic Republic of Iran Concerning the Use of Chemical Weapons*, S/16433. (26 March 1984), pp. 11-12.
- 3. Over 10,000 casualties were reported. See Edward M. Spiers, *Chemical and Biological Weapons: A Study in Proliferation* (St. Martin's Press: New York, NY, 1994), p 18; N. Kirkham 'Cyanide Bombers Lay Waste a Town', *The Daily Telegraph*, 22 March 1988, p. 1.
- 4. C. E. Heller, *Leavenworth Papers. Chemical Warfare in World War I: The American Experience* (Combat Studies Institute, Ft. Leavenworth, KS, 1984) pp 91-92.
- 5. J. Woodall, *Lancet*, **350**, 296 (1997).
- 6. E. T. Takafuji and A. B. Kok, in *Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare*, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) pp 118-119.
- 7. M. R. O'Hern, T. R. Dashiell, and M. F. Tracey in *Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare*, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) pp 1371-1372.
- 8. E. H. Braue, Jr. *Journal of Applied Toxicology*, **19(S)**, S47-S53 (1999).
- 9. M. J. McCreery, US Patent No. 5 607 979 (4 March 1997).
- 10. R. M. Silverstein, G. C. Bassler, T. C. Morrill, *Spectrometric Identification of Organic Compounds*, 5th ed. (John Wiley and Sons, New York, 1991), pp 160-163.
- 11. CMS Field Products Group, Birmingham, AL.
- 12. Minimal amount of HD for vesication = 1000 ng. See F. R. Sidell, J. S. Urbanetti, W. J. Smith, and C. G. Hurst in *Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare*, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) pp 201
- 13. LD₅₀ for soman (GD) = 350 mg/70 kg man. See F. R. Sidell in *Textbook of Military Medicine, Medical Aspects of Chemical and Biological Warfare*, edited by F. R. Sidell, E. T. Takafuji, and D. R. Franz (Office of the Surgeon General at TMM Publications, Washington, D. C. 1997) p 141.
- 14. J. C. Speck, US Patent No. 2 885 3058 (5 May 1959).

-
15. M. L. Shih, W. D. Korte, J. R. Smith, and L. L. Szafraniec L. *Journal of Applied Toxicology*, **19(S)**, S83-S88 (1999)

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 2001		2. REPORT TYPE Open Literature		3. DATES COVERED (From - To)	
4. TITLE AND SUBTITLE The U.S. Army Reactive Topical Skin Protectant (rTSP): Challenges and Successes				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER 63384	
6. AUTHOR(S) Hobson, ST, Lehnert, EK, Braue, EH, Jr.				5d. PROJECT NUMBER TC3	
				5e. TASK NUMBER V.E	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) US Army Medical Research Aberdeen Proving Ground, MD Institute of Chemical Defense 21010-5400 ATTN: MCMR-UV-DA 3100 Ricketts Point Road				8. PERFORMING ORGANIZATION REPORT NUMBER USAMRICD-P00-012	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research Aberdeen Proving Ground, MD Institute of Chemical Defense 21010-5400 ATTN: MCMR-UV-RC 3100 Ricketts Point Road				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES Published in Materials Research Society Symposium Proceedings, vol. 628, CC10.1.1-CC10.8.8, 2000					
14. ABSTRACT See reprint.					
15. SUBJECT TERMS nerve agents, blistering agents, skin, protection, barrier cream, reactive topical skin protectant, decontamination					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UNLIMITED	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON Stephen T. Hobson
a. REPORT UNCLASSIFIED	b. ABSTRACT UNCLASSIFIED	c. THIS PAGE UNCLASSIFIED			19b. TELEPHONE NUMBER (include area code) 410-436-2833